Effect analysis of different levels of femoston on moderate and severe intrauterine adhesions

Abstract

Objective To investigate the effect of femoston with two doses in the treatment of moderate and severe intrauterine adhesions. Methods Sixty patients with moderate and severe intrauterine adhesions were confirmed by hysteroscopy examination and American Fertility Society (AFS) grading standard. They were divided into group A and group B according to different applications femoston, each group with 30 cases. All patients were treated with transcervical resection of adhesion and received estrogen treatment for 3 months. In group A, 30 cases were all given femoston 1 mg/d. In group B, 30 cases were given femoston 2 mg/d. All patients before and after taking medications were drawed blood to test estradiol (E2) and given an ultrasound examination to measure the endometrial thickness. The adverse reactions of drug were followed up regularly during the treatment, hysteroscopy once again to evaluate uterine cavity after 3 months. Results In group A, the concentrations of E2 in serum of moderate and severe intrauterine adhesions risen to (501.67±127.04) ng/L and (550.38±135.46) ng/L, respectively, endometrium thickness was increased to (7.01±0.57) mm and (6.28±0.51) mm. In group B, the concentrations of estradiol in serum of moderate and severe intrauterine adhesions risen to (1 099.70±97.88) ng/L and (1 196.25±169.56) ng/L, endometrium thickness was increased to (6.65±0.60) mm and (5.70±0.47) mm. The concentrations of E2 in serum of group B were significantly higher than that in group A (P 0.05). In severe intrauterine adhesion, the endometrium thickness of group A was better than group B (P 0.05), and the adverse reactions of drug in group B increased obviously compared with group A. Conclusion The patients with severe intrauterine adhesions cannot increase the dosage of estrogen blindly, because it cannot increase endometrial thickness and improve the clinical effect significantly, but increase the adverse reactions of drug. Key words: Intrauterine adhesions; Femoston; Hormone supplement therapy